JP7683901B2 - 筋肉性能改善化合物 - Google Patents

筋肉性能改善化合物 Download PDF

Info

Publication number
JP7683901B2
JP7683901B2 JP2019548783A JP2019548783A JP7683901B2 JP 7683901 B2 JP7683901 B2 JP 7683901B2 JP 2019548783 A JP2019548783 A JP 2019548783A JP 2019548783 A JP2019548783 A JP 2019548783A JP 7683901 B2 JP7683901 B2 JP 7683901B2
Authority
JP
Japan
Prior art keywords
nlg3
actr
muscle
seq
myostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536818A5 (cg-RX-API-DMAC7.html
JP2019536818A (ja
Inventor
ウィレム フリーブレード，ヤン
マリア ボイド，マリナ
ブチェンコ，オレナ
シェリノ，ロベルタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmafox Therapeutics AG
Original Assignee
Pharmafox Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics AG filed Critical Pharmafox Therapeutics AG
Publication of JP2019536818A publication Critical patent/JP2019536818A/ja
Publication of JP2019536818A5 publication Critical patent/JP2019536818A5/ja
Priority to JP2023083666A priority Critical patent/JP2023116479A/ja
Application granted granted Critical
Publication of JP7683901B2 publication Critical patent/JP7683901B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019548783A 2016-11-29 2017-11-28 筋肉性能改善化合物 Active JP7683901B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023083666A JP2023116479A (ja) 2016-11-29 2023-05-22 筋肉性能改善化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1620119.6 2016-11-29
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023083666A Division JP2023116479A (ja) 2016-11-29 2023-05-22 筋肉性能改善化合物

Publications (3)

Publication Number Publication Date
JP2019536818A JP2019536818A (ja) 2019-12-19
JP2019536818A5 JP2019536818A5 (cg-RX-API-DMAC7.html) 2021-01-14
JP7683901B2 true JP7683901B2 (ja) 2025-05-27

Family

ID=58073474

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548783A Active JP7683901B2 (ja) 2016-11-29 2017-11-28 筋肉性能改善化合物
JP2023083666A Pending JP2023116479A (ja) 2016-11-29 2023-05-22 筋肉性能改善化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023083666A Pending JP2023116479A (ja) 2016-11-29 2023-05-22 筋肉性能改善化合物

Country Status (11)

Country Link
US (1) US11407799B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7683901B2 (cg-RX-API-DMAC7.html)
KR (1) KR102622245B1 (cg-RX-API-DMAC7.html)
CN (1) CN110036024B (cg-RX-API-DMAC7.html)
AU (1) AU2017367277B2 (cg-RX-API-DMAC7.html)
CA (1) CA3045245A1 (cg-RX-API-DMAC7.html)
GB (1) GB201620119D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ754625A (cg-RX-API-DMAC7.html)
WO (1) WO2018100483A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903261B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN120535607A (zh) 2018-01-12 2025-08-26 科乐斯疗法公司 激活素受体iib型变体及其使用方法
AU2019266314B2 (en) 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2023512423A (ja) * 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
EP4121090A4 (en) * 2020-03-20 2024-09-04 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A4 (en) * 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4185316A4 (en) * 2020-07-24 2024-07-17 Agency for Science, Technology and Research WOUND HEALING COMPOSITION AND USES THEREOF
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
KR20230169123A (ko) * 2021-03-10 2023-12-15 악셀레론 파마 인코포레이티드 Actrii-alk4 길항제 및 심부전을 치료하는 방법
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287151A1 (en) 2003-09-30 2005-12-29 Glass David J Secreted protein therapeutics and uses thereof
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片
JP2013511474A (ja) 2009-11-17 2013-04-04 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503673A (ja) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
US20050287151A1 (en) 2003-09-30 2005-12-29 Glass David J Secreted protein therapeutics and uses thereof
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片
JP2013511474A (ja) 2009-11-17 2013-04-04 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用

Also Published As

Publication number Publication date
KR20190085132A (ko) 2019-07-17
AU2017367277B2 (en) 2021-04-01
CN110036024A (zh) 2019-07-19
JP2023116479A (ja) 2023-08-22
US11407799B2 (en) 2022-08-09
WO2018100483A1 (en) 2018-06-07
CN110036024B (zh) 2024-05-07
AU2017367277A1 (en) 2019-07-04
EP3548509A1 (en) 2019-10-09
KR102622245B1 (ko) 2024-01-05
ZA201903261B (en) 2020-02-26
CA3045245A1 (en) 2018-06-07
US20210253654A1 (en) 2021-08-19
NZ754625A (en) 2023-03-31
GB201620119D0 (en) 2017-01-11
JP2019536818A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
JP7683901B2 (ja) 筋肉性能改善化合物
US11813315B2 (en) Fibronectin based scaffold domain proteins that bind to myostatin
JP3273792B2 (ja) Ｎｍｄａレセプターのアロステリックモジュレーター
JP5356636B2 (ja) Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
IL281549B2 (en) Preparations and methods for growth factor modulation
JP2012501973A (ja) 痛みの治療に関する薬剤及び方法
CN101094866A (zh) G蛋白耦合受体激动剂和拮抗剂及其使用方法
US20180169183A1 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
CN110536692A (zh) 用于治疗糖尿病的含有atpif1的药物组合物
Liu et al. Identification of a new functional domain of Nogo‐A that promotes inflammatory pain and inhibits neurite growth through binding to NgR1
RU2836262C1 (ru) Композиции и способы активации интегринов
KR20180120738A (ko) 톨-유사 수용체 4에 대한 길항제로서의 뉴몰리신 펩타이드의 용도 및 톨-유사 수용체 4 관련 질병을 치료하는 방법
Gao et al. Actions of GDNF on Midbrain Dopaminergic Neurons: The Signaling Pathway
WO2019002548A1 (en) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
WO2011054894A1 (en) Composition for treating insulin resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230609

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250508

R150 Certificate of patent or registration of utility model

Ref document number: 7683901

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150